bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

125 Gene List for FFPE Tissue Analyses
Supplementary Data from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

Radiographic Imaging of Case CS98 Displaying a Complete Response to Immune Checkpoint Blockade.
Supplementary Data from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

Schematic of the Digital Peak Finding Bioinformatics Approach to Detect Microsatellite Instability in Circulating Tumor DNA from Plasma.
Table S1 from First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Authors: Tao Jessica J. , Cangemi Nicholas A. , Makker Vicky , Cadoo Karen A. , Liu Joyce F. , Rasco Drew W. , Navarro Willis H. , Haqq Christopher M. , Hyman David M.
Published: April 2023

Exposure to STM 434 among 32 patients is summarized below. Abbreviations: SD, stable disease; min, minimum; max: maximum.
Supplementary Data from Characterization and Comparison of GITR Expression in Solid Tumors
Authors: Vence Luis , Bucktrout Samantha L. , Fernandez Curbelo Irina , Blando Jorge , Smith Bevin M. , Mahne Ashley E. , Lin John C. , Park Terrence , Pascua Edward , Sai Tao , Chaparro-Riggers Javier , Subudhi Sumit K. , Scutti Jorge B. , Higa Maria G. , Zhao Hao , Yadav Shalini S. , Maitra Anirban , Wistuba Ignacio I. , Allison James P. , Sharma Padmanee
Published: April 2023

Supplementary figures
Supplementary Figure 6 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Figure 6
Supplementary Data Table 3 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Authors: Wang Victoria E. , Xue Jenny Y. , Frederick Dennie T. , Cao Yi , Lin Eva , Wilson Catherine , Urisman Anatoly , Carbone David P. , Flaherty Keith T. , Bernards Rene , Lito Piro , Settleman Jeff , McCormick Frank
Published: April 2023

Table S3 shows unique mutations in A375 VCR cells compared to parental using exome sequencing
Supplementary Data S1-S3 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Authors: Wang Victoria E. , Xue Jenny Y. , Frederick Dennie T. , Cao Yi , Lin Eva , Wilson Catherine , Urisman Anatoly , Carbone David P. , Flaherty Keith T. , Bernards Rene , Lito Piro , Settleman Jeff , McCormick Frank
Published: April 2023

Figure S1 shows the A375 VCR cells being resistant and addicted to dabrafenib and trametinib (A,B), that knockdown of STAT3 had no effect on drug resistance (C,D), Caspase-Glo assays of drug-treated cells (F), and time course of pFGFR1 and pERK of drug-treated A375 parental and VCR cells (A) and Mel888 parental and VCR cells (B). Figure S2 shows suppression of pERK with BGJ398, PD173074 but not with BLU-554 compound (A), that drug-treated conditioned media can confer resistant to BRAF/MEK inhibitors and this phenomenon is extinguishable over time after withdrawal of the drugs (B), and the level of FGF1 secreted in response to single agent BRAFi or MEKi treatment (c). Figure S3 shows combined BRAF/MEK inhibition results in attenuation of xenograft tumor growth through suppression of pERK (A, B) and the triple combinations used do not result in increased toxicity as manifested by change in weight (C).
Supplementary Data from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Authors: Kaseb Ahmed O. , Sánchez Nora S. , Sen Shiraj , Kelley Robin K. , Tan Benjamin , Bocobo Andrea G. , Lim Kian H. , Abdel-Wahab Reham , Uemura Marc , Pestana Roberto Carmagnani , Qiao Wei , Xiao Lianchun , Morris Jeffrey , Amin Hesham M. , Hassan Manal M. , Rashid Asif , Banks Kimberly C. , Lanman Richard B. , Talasaz AmirAli , Mills-Shaw Kenna R. , George Bhawana , Haque Abedul , Raghav Kanwal P.S. , Wolff Robert A. , Yao James C. , Meric-Bernstam Funda , Ikeda Sadakatsu , Kurzrock Razelle
Published: April 2023

Supplemental table 1
Supplementary Data from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Authors: Kaseb Ahmed O. , Sánchez Nora S. , Sen Shiraj , Kelley Robin K. , Tan Benjamin , Bocobo Andrea G. , Lim Kian H. , Abdel-Wahab Reham , Uemura Marc , Pestana Roberto Carmagnani , Qiao Wei , Xiao Lianchun , Morris Jeffrey , Amin Hesham M. , Hassan Manal M. , Rashid Asif , Banks Kimberly C. , Lanman Richard B. , Talasaz AmirAli , Mills-Shaw Kenna R. , George Bhawana , Haque Abedul , Raghav Kanwal P.S. , Wolff Robert A. , Yao James C. , Meric-Bernstam Funda , Ikeda Sadakatsu , Kurzrock Razelle
Published: April 2023

Supplemental table 2
Supplementary Data from Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
Authors: Takenaka Masataka , Köbel Martin , Garsed Dale W. , Fereday Sian , Pandey Ahwan , Etemadmoghadam Dariush , Hendley Joy , Kawabata Ayako , Noguchi Daito , Yanaihara Nozomu , Takahashi Hiroyuki , Kiyokawa Takako , Ikegami Masahiro , Takano Hirokuni , Isonishi Seiji , Ochiai Kazuhiko , Traficante Nadia , Gadipally Sreeja , Semple Timothy , Vassiliadis Dane , Amarasinghe Kausyalya , Li Jason , Mir Arnau Gisela , Okamoto Aikou , Friedlander Michael , Bowtell David D. L.
Published: April 2023

Supplementary methods
Supplementary Data from Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer
Authors: Magbanua Mark Jesus M. , Yau Christina , Wolf Denise M. , Lee Jin Sun , Chattopadhyay Aheli , Scott Janet H. , Bowlby-Yoder Erin , Hwang E. Shelley , Alvarado Michael , Ewing Cheryl A. , Delson Amy L. , van't Veer Laura J. , Esserman Laura , Park John W.
Published: April 2023

Supplementary Figures and Tables except Table S7
Figure S4 from Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array
Authors: Li Jiuyi , Xue Yang , Wenger Anna , Sun Yingyu , Wang Zheng , Zhang Chuanbao , Zhang Yunqiu , Fekete Boglarka , Rydenhag Bertil , Jakola Asgeir Store , Jiang Tao , Carén Helena , Fan Xiaolong
Published: April 2023

Figure S4 shows PM gliomas with GBM morphology carry extensive chromosome abnormalities
Figure S3 from Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array
Authors: Li Jiuyi , Xue Yang , Wenger Anna , Sun Yingyu , Wang Zheng , Zhang Chuanbao , Zhang Yunqiu , Fekete Boglarka , Rydenhag Bertil , Jakola Asgeir Store , Jiang Tao , Carén Helena , Fan Xiaolong
Published: April 2023

Figure S3 shows the survival curve of the individually diagnosed EM and PM gliomas controlled by their morphological diagnosis.
Supplementary Data revised from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Authors: Loibl Sibylle , Treue Denise , Budczies Jan , Weber Karsten , Stenzinger Albrecht , Schmitt Wolfgang D. , Weichert Wilko , Jank Paul , Furlanetto Jenny , Klauschen Frederick , Karn Thomas , Pfarr Nicole , von Minckwitz Gunter , Möbs Markus , Jackisch Christian , Sers Christine , Schneeweiss Andreas , Fasching Peter A. , Schem Christian , Hummel Michael , van Mackelenbergh Marion , Nekljudova Valentina , Untch Michael , Denkert Carsten
Published: April 2023

Supplementary materials and tables
Supplementary Data from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Authors: Balakrishnan Ashwini , Rajan Anusha , Salter Alexander I. , Kosasih Paula L. , Wu Qian , Voutsinas Jenna , Jensen Michael C. , Plückthun Andreas , Riddell Stanley R.
Published: April 2023

Supplementary Figure Legends
Figure S5 from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Authors: Balakrishnan Ashwini , Rajan Anusha , Salter Alexander I. , Kosasih Paula L. , Wu Qian , Voutsinas Jenna , Jensen Michael C. , Plückthun Andreas , Riddell Stanley R.
Published: April 2023

FIGURE S5: Functional assessment of trispecific DARPin CAR T cells against multiple antigens
Figure S4 from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Authors: Balakrishnan Ashwini , Rajan Anusha , Salter Alexander I. , Kosasih Paula L. , Wu Qian , Voutsinas Jenna , Jensen Michael C. , Plückthun Andreas , Riddell Stanley R.
Published: April 2023

FIGURE S4: Analysis of tonic signaling and function of trispecific and monspecific DARPin CARs
Supplementary Table S1: Limitations of the camptothecins and advantages of the indenoisoquinoline TOP1 inhibitors from Targeting Topoisomerase I in the Era of Precision Medicine
Authors: Thomas Anish , Pommier Yves
Published: April 2023

Limitations of the camptothecins and advantages of the indenoisoquinoline TOP1 inhibitors
Figure S2 from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Authors: Balakrishnan Ashwini , Rajan Anusha , Salter Alexander I. , Kosasih Paula L. , Wu Qian , Voutsinas Jenna , Jensen Michael C. , Plückthun Andreas , Riddell Stanley R.
Published: April 2023

FIGURE S2: In vitro function and in vivo persistence of E01 DARPin CAR-T cells
Supplementary Data from Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma
Authors: Zhou Jian , Sanchez-Vega Francisco , Caso Raul , Tan Kay See , Brandt Whitney S. , Jones Gregory D. , Yan Shi , Adusumilli Prasad S. , Bott Matthew , Huang James , Isbell James M. , Sihag Smita , Molena Daniela , Rusch Valerie W. , Chatila Walid K. , Rekhtman Natasha , Yang Fan , Ladanyi Marc , Solit David B. , Berger Michael F. , Schultz Nikolaus , Jones David R.
Published: April 2023

Suppl. Table 5
Supp. Figure 3 from Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation
Authors: Davidson Tom B. , Lee Alexander , Hsu Melody , Sedighim Shaina , Orpilla Joey , Treger Janet , Mastall Max , Roesch Saskia , Rapp Carmen , Galvez Mildred , Mochizuki Aaron , Antonios Joseph , Garcia Alejandro , Kotecha Nikesh , Bayless Nicholas , Nathanson David , Wang Anthony , Everson Richard , Yong William H. , Cloughesy Timothy F. , Liau Linda M. , Herold-Mende Christel , Prins Robert M.
Published: April 2023

Supplementary Figure 3: Gene expression analysis shows increased transcription of activation and exhaustion genes in the PD-1+ population in glioma TILs and of antigen experienced genes in the PD-1+ population in glioma PBMCs (each dot represents a distinct patient). A) Fold change of various exhaustion markers between PD-1+ and PD-1- cells in glioma TILs and PBMCs. B) Fold change of various activation markers between the PD-1+ and PD-1- cells in glioma TILs and PBMCs. C) Fold change of various memory markers between the PD-1+ and PD-1- cells in glioma TILs and PBMCs.
Supp. Figure 2 from Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation
Authors: Davidson Tom B. , Lee Alexander , Hsu Melody , Sedighim Shaina , Orpilla Joey , Treger Janet , Mastall Max , Roesch Saskia , Rapp Carmen , Galvez Mildred , Mochizuki Aaron , Antonios Joseph , Garcia Alejandro , Kotecha Nikesh , Bayless Nicholas , Nathanson David , Wang Anthony , Everson Richard , Yong William H. , Cloughesy Timothy F. , Liau Linda M. , Herold-Mende Christel , Prins Robert M.
Published: April 2023

Supplementary Figure 2: Additional CyTOF data A) The percentage of the CD3+ PD-1+ cells from the TIL (green dots) and PBMCs (red dots) in each cluster (*P<0.05, ***P{less than or equal to}0.0005). Each dot represents a single patient. B) The median expression level of CD45RO in a subset of 10 patients (*P<0.05). C) The median expression level of CD39 in a subset of 4 patients (***P{less than or equal to}0.0005). D) The median expression level of TIGIT in a subset of 4 patients.
Table S2 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Okamoto Isamu , Sriuranpong Virote , Vansteenkiste Johan , Imamura Fumio , Lee Jong Seok , Pang Yong-Kek , Cobo Manuel , Kasahara Kazuo , Cheng Ying , Nogami Naoyuki , Cho Eun Kyung , Su Wu Chou , Zhang Guili , Huang Xiangning , Li-Sucholeiki Xiaocheng , Lentrichia Brian , Dearden Simon , Jenkins Suzanne , Saggese Matilde , Rukazenkov Yuri , Ramalingam Suresh S.
Published: April 2023

Table S2 shows the categorization of local testing methods based on assay limit of detection compared to the cobas® EGFR Mutation Test v2
Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Okamoto Isamu , Sriuranpong Virote , Vansteenkiste Johan , Imamura Fumio , Lee Jong Seok , Pang Yong-Kek , Cobo Manuel , Kasahara Kazuo , Cheng Ying , Nogami Naoyuki , Cho Eun Kyung , Su Wu Chou , Zhang Guili , Huang Xiangning , Li-Sucholeiki Xiaocheng , Lentrichia Brian , Dearden Simon , Jenkins Suzanne , Saggese Matilde , Rukazenkov Yuri , Ramalingam Suresh S.
Published: April 2023

Supplement_Clean version
Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Okamoto Isamu , Sriuranpong Virote , Vansteenkiste Johan , Imamura Fumio , Lee Jong Seok , Pang Yong-Kek , Cobo Manuel , Kasahara Kazuo , Cheng Ying , Nogami Naoyuki , Cho Eun Kyung , Su Wu Chou , Zhang Guili , Huang Xiangning , Li-Sucholeiki Xiaocheng , Lentrichia Brian , Dearden Simon , Jenkins Suzanne , Saggese Matilde , Rukazenkov Yuri , Ramalingam Suresh S.
Published: April 2023

Suplement_Tracked changes
Supplementary Table S1 from Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Authors: Okada Morihito , Kijima Takashi , Aoe Keisuke , Kato Terufumi , Fujimoto Nobukazu , Nakagawa Kazuhiko , Takeda Yuichiro , Hida Toyoaki , Kanai Kuninobu , Imamura Fumio , Oizumi Satoshi , Takahashi Toshiaki , Takenoyama Mitsuhiro , Tanaka Hiroshi , Hirano Jun , Namba Yoshinobu , Ohe Yuichiro
Published: April 2023

Participating study centers
Supplementary Data from Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Authors: Greally Megan , Chou Joanne F. , Chatila Walid K. , Margolis Matthew , Capanu Marinela , Hechtman Jaclyn F. , Tuvy Yaelle , Kundra Ritika , Daian Foysal , Ladanyi Marc , Kelsen David P. , Ilson David H. , Berger Michael F. , Tang Laura H. , Solit David B. , Diaz Luis A. , Schultz Nikolaus , Janjigian Yelena Y. , Ku Geoffrey Y.
Published: April 2023

OS analysis by gene alteration occurring in 10% or more of MSS patients
Supplementary Data from Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Authors: Greally Megan , Chou Joanne F. , Chatila Walid K. , Margolis Matthew , Capanu Marinela , Hechtman Jaclyn F. , Tuvy Yaelle , Kundra Ritika , Daian Foysal , Ladanyi Marc , Kelsen David P. , Ilson David H. , Berger Michael F. , Tang Laura H. , Solit David B. , Diaz Luis A. , Schultz Nikolaus , Janjigian Yelena Y. , Ku Geoffrey Y.
Published: April 2023

OS analysis by gene alteration occurring in 10% or more of MSS patients who received monotherapy
Supplementary Data from Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Authors: Greally Megan , Chou Joanne F. , Chatila Walid K. , Margolis Matthew , Capanu Marinela , Hechtman Jaclyn F. , Tuvy Yaelle , Kundra Ritika , Daian Foysal , Ladanyi Marc , Kelsen David P. , Ilson David H. , Berger Michael F. , Tang Laura H. , Solit David B. , Diaz Luis A. , Schultz Nikolaus , Janjigian Yelena Y. , Ku Geoffrey Y.
Published: April 2023

OS analysis by gene alteration occurring in 10% or more of MSS patients who received combination therapy
Supplemental Legend from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Authors: Ivanova Elena , Kuraguchi Mari , Xu Man , Portell Andrew J. , Taus Luke , Diala Irmina , Lalani Alshad S. , Choi Jihyun , Chambers Emily S. , Li Shuai , Liu Shengwu , Chen Ting , Barbie Thanh U. , Oxnard Geoffrey R. , Haworth Jacob J. , Wong Kwok-Kin , Dahlberg Suzanne E. , Aref Amir A. , Barbie David A. , Bahcall Magda , Paweletz Cloud P. , Jänne Pasi A.
Published: April 2023

Supplemental Legend
Figure S3 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Authors: Ivanova Elena , Kuraguchi Mari , Xu Man , Portell Andrew J. , Taus Luke , Diala Irmina , Lalani Alshad S. , Choi Jihyun , Chambers Emily S. , Li Shuai , Liu Shengwu , Chen Ting , Barbie Thanh U. , Oxnard Geoffrey R. , Haworth Jacob J. , Wong Kwok-Kin , Dahlberg Suzanne E. , Aref Amir A. , Barbie David A. , Bahcall Magda , Paweletz Cloud P. , Jänne Pasi A.
Published: April 2023

Supplemental Figure 3. Tumor volumes (TV; mean +/- SEM) over time of PDX DFCI 359 and PDX 315 dosed with neratinib (40mg/kg daily), TDM1 (20 mg/kg weekly), and their combinations (n = 8 mice/cohort). The data for the vehicle and neratinib arms for DFCI 315 are from the same experiment as in Figure 5D.
Figure S3 from Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer
Authors: Corredor Germán , Wang Xiangxue , Zhou Yu , Lu Cheng , Fu Pingfu , Syrigos Konstantinos , Rimm David L. , Yang Michael , Romero Eduardo , Schalper Kurt A. , Velcheti Vamsidhar , Madabhushi Anant
Published: April 2023

Figure S3. Boxplots corresponding to the top SpaTIL features. (a) D1, (b) D2, (c) D3, and (d) D4.
Figure S2 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Authors: Ivanova Elena , Kuraguchi Mari , Xu Man , Portell Andrew J. , Taus Luke , Diala Irmina , Lalani Alshad S. , Choi Jihyun , Chambers Emily S. , Li Shuai , Liu Shengwu , Chen Ting , Barbie Thanh U. , Oxnard Geoffrey R. , Haworth Jacob J. , Wong Kwok-Kin , Dahlberg Suzanne E. , Aref Amir A. , Barbie David A. , Bahcall Magda , Paweletz Cloud P. , Jänne Pasi A.
Published: April 2023

Supplemental Figure 2. Orthogonal assays for cell viability in drug resistant models.
Table S1, Table S2, Table S3, Table S4, Table S5, Table S6, Table S7, Table S8, Table S9, Table S10, Table S11, Figure S1, Figure S2, Figure S3, Text from Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer
Authors: Shiino Sho , Matsuzaki Juntaro , Shimomura Akihiko , Kawauchi Junpei , Takizawa Satoko , Sakamoto Hiromi , Aoki Yoshiaki , Yoshida Masayuki , Tamura Kenji , Kato Ken , Kinoshita Takayuki , Kitagawa Yuko , Ochiya Takahiro
Published: April 2023

Table S1. Definition criteria of categorical variables for logistic-LASSO regression analysis Table S2. Clinicopathological characteristics of patients with benign breast diseases Table S3. Clinicopathological characteristics of patients stratified into the training set and test set Table S4. Comparison of T staging between pre- and post-operative diagnosis Table S5. Comparison of lymphovascular invasion (LVI) between pre- and post-operative diagnosis Table S6. Clinicopathological characteristics of N-positive patients misdiagnosed as N-negative in the test set Table S7. Sensitivity and specificity analysis for the diagnostic index in the test set Table S8. Biomarker candidate miRNAs for N positivity Table S9. Comparison of post-operative lymphovascular invasion (LVI) between original and re-evaluated diagnosis in the training set Table S10. Characteristics of ultrasound findings of axillary lymph node status Table S11. Utility of ultrasonography for the detection of axillary lymph node metastasis Figure S1. Ultrasound findings of suspicious metastatic and negative axillary lymph nodes. Figure S2. Serum levels of miR-629-3p and miR-4710 in the training set. P-values were calculated by one-way ANOVA with Tukey's post-hoc analysis. Figure S3. ROC curves for histological grade and Ki-67 labeling index in the test set (postoperative pathology). Numbers in parentheses are 95% confidence intervals. Text. Materials and Methods
Supplementary Figure 1 from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Authors: Allen Bryan G. , Bodeker Kellie L. , Smith Mark C. , Monga Varun , Sandhu Sonia , Hohl Raymond , Carlisle Thomas , Brown Heather , Hollenbeck Nancy , Vollstedt Sandy , Greenlee Jeremy D. , Howard Matthew A. , Mapuskar Kranti A. , Seyedin Steven N. , Caster Joseph M. , Jones Karra A. , Cullen Joseph J. , Berg Daniel , Wagner Brett A. , Buettner Garry R. , TenNapel Mindi J. , Smith Brian J. , Spitz Douglas R. , Buatti John M.
Published: April 2023

Supplemental Figure 1: P-AscH- treatment in combination with RT and TMZ decreases the systemic the systemic oxidaitive stress marker 4-hydroxy-2-nonenal modified proteins. S1A-SAB.
Supplementary Data from Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors
Authors: Gaydosik Alyxzandria M. , Tabib Tracy , Geskin Larisa J. , Bayan Claire-Audrey , Conway James F. , Lafyatis Robert , Fuschiotti Patrizia
Published: April 2023

Supplementary Data
Supplementary Data from PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial
Authors: Kitson Sarah J. , Maskell Zoe , Sivalingam Vanitha N. , Allen Jennifer L. , Ali Saad , Burns Sean , Gilmour Kyle , Latheef Rahamatulla , Slade Richard J. , Pemberton Philip W. , Shaw Joseph , Ryder W. David , Kitchener Henry C. , Crosbie Emma J.
Published: April 2023

Supplementary methods
Figure S9 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S9
Figure S8 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S8
Figure S6 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S6
Figure S3 from Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
Authors: Dihge Looket , Vallon-Christersson Johan , Hegardt Cecilia , Saal Lao H. , Häkkinen Jari , Larsson Christer , Ehinger Anna , Loman Niklas , Malmberg Martin , Bendahl Pär-Ola , Borg Åke , Staaf Johan , Rydén Lisa
Published: April 2023

Cohen's kappa coefficient displaying the degree of inter-model agreement and barplots displaying percentage of correctly predicted cases by the derived models versus clinical N0, N1, N2 status across evaluation groups
Figure S2 from Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
Authors: Dihge Looket , Vallon-Christersson Johan , Hegardt Cecilia , Saal Lao H. , Häkkinen Jari , Larsson Christer , Ehinger Anna , Loman Niklas , Malmberg Martin , Bendahl Pär-Ola , Borg Åke , Staaf Johan , Rydén Lisa
Published: April 2023

Functional pathway analyses displaying the biological processes associated with nodal metastasis predicted by the GEX and MIXED models
Figure S1 from Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
Authors: Dihge Looket , Vallon-Christersson Johan , Hegardt Cecilia , Saal Lao H. , Häkkinen Jari , Larsson Christer , Ehinger Anna , Loman Niklas , Malmberg Martin , Bendahl Pär-Ola , Borg Åke , Staaf Johan , Rydén Lisa
Published: April 2023

Performance of seven machine-learning models in the prediction of nodal metastasis in the development cohort
Supplementary Data_Figure legends from YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer
Authors: Yun Jiyeon , Hong Min Hee , Kim Seok-Young , Park Chae-Won , Kim Soyoung , Yun Mi Ran , Kang Han Na , Pyo Kyoung-Ho , Lee Sung Sook , Koh Jong Sung , Song Ho-Juhn , Kim Dong Kyun , Lee Young-Sung , Oh Se-Woong , Choi Soongyu , Kim Hye Ryun , Cho Byoung Chul
Published: April 2023

Supplementary Figure legend
Supplementary Figure Legends & Tables from The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
Authors: Schaer David A. , Geeganage Sandaruwan , Amaladas Nelusha , Lu Zhao Hai , Rasmussen Erik R. , Sonyi Andreas , Chin Darin , Capen Andrew , Li Yanxia , Meyer Catalina M. , Jones Bonita D. , Huang Xiaodong , Luo Shuang , Carpenito Carmine , Roth Kenneth D. , Nikolayev Alexander , Tan Bo , Brahmachary Manisha , Chodavarapu Krishna , Dorsey Frank C. , Manro Jason R. , Doman Thompson N. , Donoho Gregory P. , Surguladze David , Hall Gerald E. , Kalos Michael , Novosiadly Ruslan D.
Published: April 2023

Supplementary Figure Legends & Tables
Supplementary Data from The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
Authors: Schaer David A. , Geeganage Sandaruwan , Amaladas Nelusha , Lu Zhao Hai , Rasmussen Erik R. , Sonyi Andreas , Chin Darin , Capen Andrew , Li Yanxia , Meyer Catalina M. , Jones Bonita D. , Huang Xiaodong , Luo Shuang , Carpenito Carmine , Roth Kenneth D. , Nikolayev Alexander , Tan Bo , Brahmachary Manisha , Chodavarapu Krishna , Dorsey Frank C. , Manro Jason R. , Doman Thompson N. , Donoho Gregory P. , Surguladze David , Hall Gerald E. , Kalos Michael , Novosiadly Ruslan D.
Published: April 2023

Figure S1. Efficacy of pemetrexed in Lewis Lung carcinoma model and metabolomic analysis of MC38 tumor bearing mice treated with 50 mg/kg of pemetrexed Figure S2. T cell inflamed phenotype induced by pemetrexed is modestly reduced in tumors upon combination with cisplatin Figure S3. Combination Effects of pemetrexed -/+ anti-PD-L1 in MC38, LLC and Colon26 tumor models Figure S4 (A) Mice bearing Colon26 tumors were treated starting 10 days after tumor implantation with pemetrexed (50 mg/kg, 5 days on, 2 days off, IP) and/or anti-PD-L1 (αPD-L1) (500 ug/mouse, weekly IP), and tumors were isolated after 14 days of treatment and single cell suspensions were subjected to flow cytometry analysis. FACS plots show representative data of intra-tumor CD45+ tumor-infiltrating lymphocyte (TIL) T cell (CD3+) and Myeloid cell (CD11b+) subsets frequencies; and percentage of Ki67+ CD4+ T effector cells based on the gating scheme indicated. (B) Spleens, TDLNs and tumors were isolated and antigen specific T cell responses were measured by IFNγ ELISpot, gp70 Tetramer staining (Tet) and Intracellular cytokine staining. (Left) CD8 T cells isolated from pooled spleens and TDLNs from individual mice were cultured alone (control) with irrelevant BALB/c tumor EMT6 or cognate Colon26 tumor cells overnight and number of IFNγ producing T cells was measured by ELISpot. (Middle) Freshly isolated CD8+ T cells from spleens and TDLNs were assessed for % of gp70 Tet+ cells. (Right) Freshly isolated tumors single cell suspensions were stimulated with PMA/ phorbol myristate acetate (PMA) and ionomycin with monensin for 4 hrs and the % of TNF-alpha positive and gp70 Tet+ CD8 T cells were measured from the Live CD45+, CD3+ T cells by FACS. Figure S5. Concordance between QuantiGene and nCounter gene expression data for in vitro activated T cells treated in the presence or absence of pemetrexed (related to Figure 6F). Supplementary Table 1. Ingenuity pathway analysis (IPA) of MC38 tumors treated with pemetrexed or paclitaxel with or without carboplatin Supplementary Table 2: IPA results for Colon26 experiment in Figure 4 sorted by functional class. Pemetrexed monotherapy in this experiment at this timepoint did not have enough differentially expressed genes to generate IPA results.
Supplementary Data from Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study
Authors: Paoletti Costanza , Miao Jieling , Dolce Emily M. , Darga Elizabeth P. , Repollet Madeline I. , Doyle Gerald V. , Gralow Julie R. , Hortobagyi Gabriel N. , Smerage Jeffrey B. , Barlow William E. , Hayes Daniel F.
Published: April 2023

Supplementary Figure Legend: Supplementary Figure 1.: S1A.; S1B; Supplementary Figure 2.; Supplementary Figure 3.: S3A.; S3B.; S3C.; S3D.; Supplementary Figure 4.: S4A.; S4B.; S4C.; Supplementary Figure 5.: S5A.; S5B.; S5C.; Supplementary Figure 6.: S6A.; S6B.; S6C.; Supplementary Figure 7: S7A.; S7B; S7C. Tables: Supplementary Table S1.; Supplementary Table S2.: S2A; S2B; S2C; Supplementary Table S3.: S3A; S3B; S3C; Supplementary Table S4. Original Concept
Supplementary Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
Authors: Yeung Tsz-Lun , Leung Cecilia S. , Yip Kay-Pong , Sheng Jianting , Vien Long , Bover Laura C. , Birrer Michael J. , Wong Stephen T.C. , Mok Samuel C.
Published: April 2023

Supplementary Table 1
Supplementary Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
Authors: Yeung Tsz-Lun , Leung Cecilia S. , Yip Kay-Pong , Sheng Jianting , Vien Long , Bover Laura C. , Birrer Michael J. , Wong Stephen T.C. , Mok Samuel C.
Published: April 2023

Supplementary Table 2
Figure S5 from A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues
Authors: Natarajan Arutselvan , Patel Chirag B. , Ramakrishnan Sindhuja , Panesar Paramjyot S. , Long Steven R. , Gambhir Sanjiv S.
Published: April 2023

Figure S5 from A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues
Supplementary Data from Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
Authors: Sundaravel Sriram , Kuo Wen-Liang , Jeong Jong Jin , Choudhary Gaurav S. , Gordon-Mitchell Shanisha , Liu Hui , Bhagat Tushar D. , McGraw Kathy L. , Gurbuxani Sandeep , List Alan F. , Verma Amit , Wickrema Amittha
Published: April 2023

Supplemental figure 4: Twenty four hours post siRNA nucleofection immunoblotting analysis was performed to test knockdown of A) LYN, B) SHP1 and C) SHIP1 in primary HSCs.
Supplementary Materials from Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation Enteropathy
Authors: Reis Ferreira Miguel , Andreyev H. Jervoise N. , Mohammed Kabir , Truelove Lesley , Gowan Sharon M. , Li Jia , Gulliford Sarah L. , Marchesi Julian R. , Dearnaley David P.
Published: April 2023

Supplementary materials document.
Supplementary Data File from Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation Enteropathy
Authors: Reis Ferreira Miguel , Andreyev H. Jervoise N. , Mohammed Kabir , Truelove Lesley , Gowan Sharon M. , Li Jia , Gulliford Sarah L. , Marchesi Julian R. , Dearnaley David P.
Published: April 2023

Data used in study analyses
Supplementary Figure Legends from A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer
Authors: Sjöberg Elin , Meyrath Max , Milde Laura , Herrera Mercedes , Lövrot John , Hägerstrand Daniel , Frings Oliver , Bartish Margarita , Rolny Charlotte , Sonnhammer Erik , Chevigné Andy , Augsten Martin , Östman Arne
Published: April 2023

Supplementary Figure Legends
Supplementary Table S6 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S6
Table S4 from NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer
Authors: Gambardella Valentina , Gimeno-Valiente Francisco , Tarazona Noelia , Ciarpaglini Carolina Martinez , Roda Desamparados , Fleitas Tania , Tolosa Pablo , Cejalvo Juan Miguel , Huerta Marisol , Roselló Susana , Castillo Josefa , Cervantes Andrés
Published: April 2023

Patients characteristics
Supplementary Table 4 from Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy
Authors: de Roest Reinout H. , Mes Steven W. , Poell Jos B. , Brink Arjen , van de Wiel Mark A. , Bloemena Elisabeth , Thai Elena , Poli Tito , Leemans C. René , Brakenhoff Ruud H.
Published: April 2023

Table with detailed results of target enrichment sequencing.
Figure S1 from NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer
Authors: Gambardella Valentina , Gimeno-Valiente Francisco , Tarazona Noelia , Ciarpaglini Carolina Martinez , Roda Desamparados , Fleitas Tania , Tolosa Pablo , Cejalvo Juan Miguel , Huerta Marisol , Roselló Susana , Castillo Josefa , Cervantes Andrés
Published: April 2023

Trastuzumab resistance in LR1NCI
Supplementary Table 2 from Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy
Authors: de Roest Reinout H. , Mes Steven W. , Poell Jos B. , Brink Arjen , van de Wiel Mark A. , Bloemena Elisabeth , Thai Elena , Poli Tito , Leemans C. René , Brakenhoff Ruud H.
Published: April 2023

Table with genepanel of the target enrichment sequencing.
Supplementary Figures from Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Authors: Dagogo-Jack Ibiayi , Rooney Marguerite , Lin Jessica J. , Nagy Rebecca J. , Yeap Beow Y. , Hubbeling Harper , Chin Emily , Ackil Jennifer , Farago Anna F. , Hata Aaron N. , Lennerz Jochen K. , Gainor Justin F. , Lanman Richard B. , Shaw Alice T.
Published: April 2023

Supplementary Figures
Supplementary Table 1 from Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy
Authors: de Roest Reinout H. , Mes Steven W. , Poell Jos B. , Brink Arjen , van de Wiel Mark A. , Bloemena Elisabeth , Thai Elena , Poli Tito , Leemans C. René , Brakenhoff Ruud H.
Published: April 2023

Patient characteristics
Supplementary Figure Legends from Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Authors: Dagogo-Jack Ibiayi , Rooney Marguerite , Lin Jessica J. , Nagy Rebecca J. , Yeap Beow Y. , Hubbeling Harper , Chin Emily , Ackil Jennifer , Farago Anna F. , Hata Aaron N. , Lennerz Jochen K. , Gainor Justin F. , Lanman Richard B. , Shaw Alice T.
Published: April 2023

Supplementary Figure Legends
Table S1-S9 from Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Authors: Chen Kezhong , Zhao Heng , Shi Yanbin , Yang Fan , Wang Lien Tu , Kang Guannan , Nie Yuntao , Wang Jun
Published: April 2023

Table S1. Clinical features of 26 enrolled patients. Table S2. The linear regression formula, slope K and coefficient of correlation R2 for each curve. Table S3. The plasma ctDNA concentrations from time A to time D in the half-life analyzed patients. Table S4. Correlation between clinical characteristics and the plasma ctDNA concentration at times P1, P2 and P3. Table S5. The exact time interval from tumor resection to the series of scheduled time point (Time B to Time P2). Table S6. Plasma DNA metrics and ctDNA content analysis at each time point for 26 patients. Table S7. Adjacent normal tissue and Tumor tissue DNA metrics for 26 patients. Table S8. Detailed gene mutation informations for all tumors and each time point plasmas. Table S9. White blood cell DNA metrics for 26 patients.
Supplemental Data from First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Authors: Piha-Paul Sarina A. , Sachdev Jasgit C. , Barve Minal , LoRusso Patricia , Szmulewitz Russell , Patel Sapna Pradyuman , Lara Primo N. , Chen Xiaotian , Hu Beibei , Freise Kevin J. , Modi Dimple , Sood Anjla , Hutti Jessica E. , Wolff Johannes , O'Neil Bert H.
Published: April 2023

Supplemental Methods, Figures S1-S5, Tables S1-S7
Supplementary Data from 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers
Authors: Yang Hailing , Shu Zhang , Jiang Yongying , Mao Weiqun , Pang Lan , Redwood Abena , Jeter-Jones Sabrina L. , Jennings Nicholas B. , Ornelas Argentina , Zhou Jinhua , Rodriguez-Aguayo Cristian , Bartholomeusz Geoffrey , Iles LaKesla R. , Zacharias Niki M. , Millward Steven W. , Lopez-Berestein Gabriel , Le Xiao-Feng , Ahmed Ahmed A. , Piwnica-Worms Helen , Sood Anil K. , Bast Robert C. , Lu Zhen
Published: April 2023

Supplementary Data and Methods
Figure S1-S7 from Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Authors: Chen Kezhong , Zhao Heng , Shi Yanbin , Yang Fan , Wang Lien Tu , Kang Guannan , Nie Yuntao , Wang Jun
Published: April 2023

Figure S1. (A) Strategy for plasma detection of oncogenic mutations. The exonic positions and nature of the hotspot mutations are shown. Two sets of bidirectional reverse primers (arrows) were positioned to robust sequences on either side of each mutation site to target and amplify each allele by inverse PCR. For detection of ALK fusions, targeting primers were progressively spaced across exon 19, intron 19, and exon 20, spanning the known ALK breakpoint region. (B) Hot Spot Gene Mutations and Diagnostic cSMART Primers. Figure S2. Comparison of the distributions of driver mutations identified in 26 matched tDNA and plasma ctDNA samples. Thirty-two mutations were detected in the plasma at time A, including 14 TP53 mutations, 8 EGFR mutations, 6 PIK3CA mutations, 3 KRAS mutations and 1 ALK mutation. Five patients had two mutations simultaneously in the plasma ctDNA: case 3 had PIK3CA and EGFR mutations; case 6 had EGFR and TP53 mutations; case 15 had two different TP53 mutations, namely, a base substitution mutation in exon 5 and a base substitution mutation in exon 8; case 17 had EGFR and TP53 mutations; and case 20 had KRAS and PIK3CA mutations simultaneously. A single mutation was detected in the other 21 cases. For the corresponding tumor tissues, a total of 29 gene mutations were detected: 14 TP53 mutations, 8 EGFR mutations, 5 PIK3CA mutations and 2 KRAS mutation. More than one mutation was detected in the tumors of 5 patients, which was completely consistent with the ctDNA results. (A) Numbers of gene mutations in tDNA vs. plasma ctDNA from matched sample pairs. (B) The inner circle shows the distribution of gene mutations, and the outer ring shows specific alterations in amino acids. Figure S3. Excluded two positive plasma A patients with CHIP validated by normal lung tissue and white blood cell. Figure S4. The plasma ctDNA concentration at each time point during the perioperative period (from time A to time P2). The X-axis represents the logarithmic value of time. Figure S5. Longitudinal ctDNA profiles of non-relapse or non-progression cases. Red curve represents the fluctuation of ctDNA concentration over time. The X-axis represents the days of post-operation. The Y-axis represents the ctDNA MAF (%). In this figure, rectangular frames represent the treatment that patients have received, as shown at the bottom, green frame: surgical treatment; yellow frame: chemotherapy; blue frame: radiotherapy and red frame: target therapy. Figure S6. The RFS (left) and OS (rightï¼‰between different ctDNA statuses at time P3 (Three cases with no blood samples at this time point were excluded). Figure S7. The RFS between patients who received postoperative therapy or not based on different strategy. (A) Patients with stage II, III and above lung cancer according to TNM stage in our study. (B) Patients with positive MRD detection in our study. (C) Patient with positive ctDNA at time P2.
Supplementary Legend from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

Supplementary Legend
Suppl. Fig. 5 from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

Long-lasting immune memory in triple-treated mice cured from C51 tumors.
Supplementary Figures from Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Authors: Hamid Omid , Molinero Luciana , Bolen Christopher R. , Sosman Jeffrey A. , Muñoz-Couselo Eva , Kluger Harriet M. , McDermott David F. , Powderly John D. , Sarkar Indrani , Ballinger Marcus , Fassò Marcella , O'Hear Carol , Chen Daniel S. , Hegde Priti S. , Hodi F. Stephen
Published: April 2023

Figures S1-S4
Suppl. Fig. 1 from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

Tumor growth suppression by cisplatin.
Supplementary Video from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Video
Figure S1 from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Authors: Vij Ravi , Nath Rajneesh , Afar Daniel E.H. , Mateos María-Victoria , Berdeja Jesús G. , Raab Marc S. , Guenther Andreas , Martínez-López Joaquín , Jakubowiak Andrzej J. , Leleu Xavier , Weisel Katja , Wong Shekman , Gulbranson Scott , Sheridan James P. , Reddy Anita , Paiva Bruno , Singhal Anil , San-Miguel Jesús F. , Moreau Philippe
Published: April 2023

Study design schematic. N, number of patients in each dose group; PK/PD, pharmacokinetics/pharmacodynamics.
Table S7 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Associations of APOBEC3 and UNG polymorphisms with HBV persistence / clearance
Table S6 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Associations of APOBEC3 and UNG polymorphisms with the risk of HCC in genotype C and B HBV-infected patients
Supplementary Figure 6 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 6